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Abstract (195 words) 
 
Skin conditions may have a major impact on the psychological well-being of 
patients, ranging from depression to anxiety. The Dermatology Life Quality 
Index (DLQI) is the most commonly used quality of life tool in dermatology, 
though it has yet to be correlated with psychiatric measures used in clinical 
therapeutic trials.  
We conducted a systematic review to determine whether there is any 
correlation between the DLQI and psychiatric measure scores, potentially 
allowing the DLQI to be used as a surrogate measure for depression or 
psychiatric screening. Six databases were searched using the keywords: 
‘DLQI’, ‘Dermatology Life Quality Index’, ‘Psych*’, ‘depression’, ‘anxiety’, 
‘stress’ and ‘trial*’. All randomised trials where full DLQI and psychiatric 
scores were provided were included. PRISMA guidelines were followed. 
462 records were screened but only seven met inclusion criteria. Hospital 
Anxiety and Depression Scale (HADS) was the most commonly used 
psychiatric measure; the ‘depression’ component score changes correlated 
strongly with the DLQI (r=0.715). 
There needs to be guidance on psychiatric measurement and reporting in 
clinical trials. Though the DLQI correlated well with the ‘depression’ domain of 
the HADS scale, interviews and screening for depression are still vital for full 
assessment of patient psychological well-being. 
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Introduction 
 
Skin conditions may have significant implications on a patient’s quality of life 
(QoL), affecting various aspects of their day-to-day living.1 This includes 
routine activities, household chores, social interactions, and relationships. 
There is a well-documented impact on psychological well-being, often 
manifesting in psychiatric problems that may range from depression to 
anxiety.2 Several studies have examined the relationship between psychiatric 
morbidity and skin diseases.3-7 For example, psoriasis is associated with 
psychologic disorders with sexual and sleep complaints being the most 
prevalent.3  Anxiety and depression are strongly correlated in such conditions 
as alopecia areata,4 vitiligo,5 rosacea,6 and hirsutism.7 
 
The Dermatology Life Quality Index8 (DLQI, score range 0-3) has been used 
in many skin conditions and across a wide range of disease severities.9,10 It is 
a dermatology-specific tool that assesses the QoL impairment in the past 
week for those aged 16 and above. It has 10 questions and evaluates 6 
parameters: symptoms and feelings, daily activities, leisure, work/school, 
personal relationships, and treatment. The total possible score ranges from 0 
to 30 where a higher score signifies a larger impairment in the patient’s QoL 
caused by the skin disease. The minimal clinically important difference 
(MCID), i.e. the minimum change in score that has clinical relevance, is 4 11 
and score ranges have also been banded to aid interpretation of QoL severity. 
12 It has high patient acceptability,13 short completion time of around two 
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minutes 14 and extensive validation,9 resulting in its widespread use in both 
clinical settings and clinical therapeutic research trials globally.15  The DLQI is 
also integral to several national registries and guidelines, for example the 
National Institute for Health and Clinical Excellence (NICE) guidelines for 
biologics in the treatment of psoriasis. 10  The psychosocial aspects captured 
by the DLQI are well documented.10 Despite this, the DLQI has yet to be 
compared and correlated with other psychiatric morbidity measures in 
randomized controlled trials. 
 
We have conducted a systematic review to identify the various validated 
psychiatric measures that have been utilized in conjunction with the DLQI in 
randomized controlled trials (RCTs).  This might also reveal whether there is 
any correlation between the scores that would potentially allow the DLQI to be 
used as a surrogate measure for depression or psychiatric screening. 
 
Materials and Methods 
 
Data sources 
 
Six computerized bibliographic databases were searched up to 19 May 2016:  
OVID MEDLINE, MEDLINE In-Process & Other Non-Indexed Citations, 
EMBASE, WEB OF SCIENCE Core Collection, SCOPUS and PsycInfo. The 
search was not restricted by language and was conducted using PRISMA 
guidelines.  
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Keywords used were: ‘DLQI’, ‘Dermatology Life Quality Index’, ‘Psych*’, 
‘depression’, ‘anxiety’, ‘stress’ and ‘trial*’. 
Search filters are given in the Supplementary Material. We ran supplementary 
searches and reviewed trial registers and grey literature. Reference lists of all 
included studies and of recent reviews were also assessed. Electronic 
publications in advance of print were also included. 
 
Selection criteria 
 
We included all randomized controlled trials for any condition where the DLQI 
was used. This included cross-over trials and trials with open-label 
extensions, in all languages studying the adult population (aged 18 and over) 
of either sex and of any ethnicity. Only papers where the absolute scores or 
change in scores for the DLQI and for psychiatric measures were provided 
were included. 
 
Exclusion criteria 
 
The exclusion criteria for the systematic review were as follows: studies which 
included any patient less than 18 years of age, and presentations where the 
change in scores could not be reliably calculated for the DLQI or any 
psychiatric morbidity scale (including graphical representation). Abstracts and 
posters were excluded where further data were not available after contacting 
the author.  
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Outcome measures extracted 
Primary Outcome 
 
Data recorded included DLQI scores and those psychiatric morbidity scale 
being utilized. Scores for these measures were recorded at baseline, 
treatment, and follow-up endpoints, as well as the change in these scores 
attributed to treatment. For studies with an open label extension, the data 
were only extracted for the period of the study randomized and controlled.  
Secondary Outcomes 
 
Correlation between the sensitivity of the DLQI and psychiatric measures to 
change. 
 
Data extraction and synthesis 
 
Two reviewers (FA and NJ) extracted data independently from all eligible 
published studies, discussed any disagreements and, if necessary involved a 
third reviewer (Dr. Jui Vyas, Cardiff University) for resolution. We adapted a 
form, which included the Cochrane Risk of Bias tool, for recording data16 that 
included study design, details of administration, methodologic quality and 
duration of treatment and follow-up. The quality of each presentation was 
quantitatively rated using the JADAD score.17  
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Results 
 
Characteristics and attributes of the studies selected 
 
462 records were screened from the initial database search, of which only 
seven interventional RCTs met the inclusion criteria; six studies were for 
psoriasis and one for atopic dermatitis. One study, for which results were 
available, was identified by searching trial registries (Fig. 1). The data 
described results from 5578 adult patients, with an average age of 45 years. 
Approximately 63.8% of the study population were men. Table 1 contains the 
studies identified by the systematic review. 
 
The most common psychiatric tools used alongside the DLQI were: Beck 
Depression Inventory (BDI, 2 studies) and the Hospital Anxiety and 
Depression Scale (HADS, 5 studies). The BDI, published in 1961,25 is a 21-
item patient reported outcome measure (score range 0-63) and is commonly 
used in studies to assess the severity of depression. The inventory covers 
various aspects of mental health and depression as well as physical 
symptoms and relationships. The HADS scale was developed in 1983 26 as a 
screening tool and consists of 14 items (score range 0-21). The questions 
encapsulate two domains: anxiety (HADS-A) and depression (HADS-D), each 
containing seven questions with a four-level response system. Scores ranging 
from 0-7 are considered ‘normal’, 8-10 ‘borderline abnormal’ and 11-21 
‘abnormal’. 
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DLQI and the psychiatric measures scores 
 
Mean scores at baseline ranged from 6.6-13.8 for the DLQI, 8.1-12.3 for the 
BDI, 5.0-6.6 for HADS-D and 6.8-8.3 for the HADS-A. At treatment endpoint, 
the scores ranged from 2.6-6.1 for the DLQI, 5.8-10.5 for BDI, 3.1-5.00 for 
HADS-D, 4.3-6.1 for HADS-A (Table 2) In five studies, the DLQI was 
measured more frequently than the psychiatric scores throughout the study 
duration; however, only measurement scores for simultaneous assessment 
points of the two measures (i.e. DLQI, HADS or BDI) were examined.  
 
Relationships between the DLQI and psychiatric measures 
 
Change in score for these measures at treatment endpoint were recorded, or 
calculated where needed from the absolute data provided. As the HADS was 
the most commonly used tool (5 out of 7 studies), DLQI scores were 
correlated with this measure (Figure 2a and 2b). Both domains of the HADS 
were strongly correlated to the DLQI (HADS-D index: R2=0.715, and HADS-A 
index: R2=0.423). 
 
Relevance of accumulative change of scores for the DLQI and HAD 
Scale 
 
Table 2 demonstrates a mean baseline HADS-D score across all studies of 
5.8 (‘normal’ according to the HADS-D scoring index26) and a mean baseline 
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HADS-A score of 7.4 (‘borderline abnormal’). The expected DLQI score 
change per HADS-D point is 4.59 and 4.29 for the HADS-A. This suggests 
that there is a relationship between the two scales, where improvement in 
DLQI scores may indicate incremental changes in HADS scores. 
 
Discussion 
 
Depression and other psychiatric issues continue to be significant problems 
experienced by dermatology patients, potentially affecting treatment 
compliance, leading to premature treatment discontinuation and alteration of 
the disease course.27 The implications extend beyond QoL for concerned 
individuals, with concurrent economic repercussions through lost productivity 
and sick leave.28, 29 Researchers often administer QoL tools which 
encompass a psychological component alongside psychiatric measures 
where appropriate to gather holistic efficacy data, though these are 
predominantly cited as secondary outcomes. This systematic review 
highlights the need for more frequent psychiatric assessment in RCTs, 
particularly where quality of life is measured; several studies had to be 
excluded from this review as a result. Full scores for psychiatric measures are 
not always provided, with researchers favoring clinical data. While primary 
outcomes are centered around these clinical parameters, psychiatric morbidity 
should not be sidelined, given its prevalence in this population.2-7  
 
Although the HADS is commonly used to assess symptoms of depression and 
anxiety, it is most appropriate as a screening tool with routine clinical 
	 11	
psychiatric assessment considered as the primary diagnostic method.30 The 
DLQI contains questions on various aspects of quality of life, including 
‘embarrassment’ and ‘self-consciousness,’ but it does not overtly record data 
on depression or anxiety.8  The total DLQI score correlates well with score 
changes in the Depression component of the HADS, though not as well as 
with the Anxiety component (Figures 2a/b). It may be possible to consider 
depression and anxiety in patients using DLQI scores, especially in the 
absence of an appropriate psychiatric measure; a DLQI score change of 4.59 
and 4.29 results in a point change for the HADS-D and HADS-A respectively. 
However, a significant limitation of this systematic review is that there was 
very little data in interventional trials where both DLQI and HADS values were 
provided, thereby necessitating further work on more expansive datasets for 
more accurate and refined correlation values. 
 
Several studies used inappropriate or non-validated scales to assess 
psychiatric morbidity, which led to their exclusion in this systematic review. 
The frequency at which this data was recorded compared to quality of life also 
varied across studies, despite majority of the identified studies belonging to 
the same intervention group. Generic and disease-specific QoL 
questionnaires may capture elements of depression and other mental health 
disorders, though these have not been validated as such for their primary 
purpose. Where psychiatric scores were provided, on occasion, the authors 
omitted commenting on the results and therefore deducing worthwhile 
conclusions. We suggest guidelines to ensure routine and correct 
measurement of psychiatric symptoms using appropriate measures, alongside 
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QoL assessment. The diverse and inconsistent nature of the data-reporting 
limits the potential to analyse and compare data between trials, whilst 
potentially missing cases of depression or other significant mental health 
issues. Almost all the studies identified in this review assessed psoriasis, a 
condition commonly linked with psychological distress.31 In such cases, 
psychotherapy may be a significant adjuvant to traditional topical and 
systemic dermatological treatment, further highlighting the need for full and 
accurate reporting of psychological data. 
 
There are several limitations to this review. Though the focus was primarily on 
interventional studies, to capture more extensive correlation data, 
observational studies could also have been included. We only studied DLQI 
data given its widespread implementation15; further research correlating other 
QoL measures may highlight other patterns of data reporting. The mean 
baseline HADS-D score of 5.8 is rated ‘normal’ according to the screening 
cut-off 26 and 7.4 ‘borderline abnormal’ for the HADS-A. This highlights that 
mostly patients without, or with minimal, psychiatric morbidity were recruited, 
emphasizing the limited availability of such data in trials. Perhaps, if data with 
patients suffering with more significant psychiatric morbidity were available for 
RCTs, we might see higher score changes in the HAD scale, and 
subsequently more sensitive DLQI correlation values (Table 2). 
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Conclusions 
 
The results of this systematic review echo our recent calls for guidance on the 
reporting of QoL scores15; we extend these suggestions for psychiatric 
morbidity reporting. Given the widespread adoption of the DLQI by healthcare 
policy makers, it is important that clinicians understand its potential value in 
informing routine decision-making. 32 Chronic skin conditions are associated 
with impaired QoL and morbidity rather than mortality, and thus such 
questionnaires are perceived to be more relevant by patients. This in turn 
encourages patients to be more actively involved in their healthcare decisions. 
33 Though skin disease are assessed using clinical parameters, their visible 
nature means patients often suffer with depression and suicidal ideation. 30 If 
appropriate measures such as the HADS are not administered, these 
potentially-serious symptoms may be missed, perhaps leading to avoidable 
detrimental consequences.  
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Figure 1 Flow diagram of publication selection 
																						
Records	identified	through	database	searching	(n	=	462)	- Medline	/	Medline	in	Progress	/	EMBASE	/	PsycINFO	(n	=	199)	- Scopus	(n=107)	- Web	of	Science	(n=156)	
Additional	records	identified	through	other	sources	- Trial	registries	(n=1)		
First	screening	(after	duplicates	removed)		(n=263)		
Full-text	articles	assessed	for	eligibility		(n=86)		
Records	excluded	on	basis	of	title	and	abstract		(n=177)		
Full-text	articles	excluded	with	reasons		(n=72)		
Articles	included	in	the	systematic	review			(n=7)		 Reasons	for	exclusion	• Not	a	randomised	controlled	trial	(n=34)	• Psychiatric	measures	not	used	(n=38)	• Full	QoL/psychiatric	data	not	provided	(n=6)	
• Subanalysis	(n=1)		
Identif
ication
	
Screen
ing	
Eligibil
ity	
Include
d	
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Figures	2a	&	b		 a) Correlation	between	change	in	DLQI	scores	and	HADS-D	scores	b) Correlation	between	change	in	DLQI	scores	and	HADS-A	scores		
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Table	1	Table	of	included	studies,	basic	demographic	information,	and	psychiatric	measures	used				
Author, 
Year 
JADAD 
score 
Interventional 
study arm 
Condition Study 
duration 
(weeks) 
Average 
participant 
age 
Total no. of 
study 
participants 
Psychiatric 
measure 
used 
Bostoen 
201218 
4 Educational 
Programme 
Atopic 
dermatitis 
12 38.5 16 BDI 
Bundy 
201319 
2 eTIPS* Psoriasis 6 45.8 61 HADS 
Dauden 
200920 
1 Etanercept 
(Continuous) 
 
Psoriasis 
 
54 
44.8 352  
HADS 
Etanercept 
(Paused) 
45.2 359 
Gelfand 
200821 
1 Etanercept 
(Continuous) 
 
Psoriasis 
 
12 
45.8 1272  
BDI 
Etanercept 
(Interrupted) 
44.9 1274 
Gniadeck
i 201222 
3 Etanercept BIW†  
Psoriasis 
 
12 
46.1 379  
HADS 
Etanercept QW†† 46.9 373 
Langley 
201023 
4 Ustekinumab 45 
mg 
 
Psoriasis 
 
52 
45.1 409  
HADS 
Ustekinumab 90 
mg 
46.6 411 
Trial No: 
NCT0130
973724 
N/A CP-690,550  
5 mg 
 
Psoriasis 
 
52 
45.9 331  
HADS 
CP-690,550 10 
mg 
44.3 341 
 
* eTIPS, electronic Targeted Intervention for Psoriasis 
† BIW, twice weekly 
†† QW, once weekly 
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Table 2 Baseline scores and change in scores after treatment as reported in 
each study 
 
Author, 
Year 
Interventiona
l study arm 
Baseline 
score 
HADS-D  
Baseline 
score 
HADS-A 
Baseline 
score 
DLQI 
Change 
in score 
HADS-D 
Change 
in score 
HADS-A  
 
Change 
in score 
DLQI 
Expected 
DLQI 
score 
change for 
1 HADS-D 
point 
Expected 
DLQI 
score 
change for 
1 HADS-A 
point  
Bundy 
201319 
eTIPS* 5.0 7.6 6.6 -0.6 -0.8 -2.5 4.0 3.2 
 
Dauden 
200920 
Etanercept 
(Continuous) 
5.7 7.2 12.8 -1.8 -2.0 -8.8 5.0 4.4 
 
Etanercept 
(Paused) 
6.2 7.7 13.8 -1.5 -1.8 -7.7 5.0 4.2 
 
Gniade
cki 
201222 
Etanercept 
BIW† 
6.6 8.3 12.3 -1.6 -1.9 -7.9 4.9 4.2 
 
Etanercept 
QW†† 
6.4 8.0 12.3 -1.4 -1.7 -6.8 4.9 4.0 
 
Langley 
201023 
Ustekinumab 
45 mg 
4.9 6.8 12.2 -1.7 -1.6 -9.3 5.4 5.8 
 
Ustekinumab 
90 mg 
5.4 6.9 12.6 -2.1 -1.6 -10.0 4.8 6.3 
 
Trial 
No: 
NCT013
0973724 
CP-690,550  
5 mg 
6.0 7.1 13.2 -2.4 -2.7 -8.2 3.4 3.0 
 
CP-690,550 
10 mg 
5.6 6.9 12.7 -2.5 -2.6 -9.4 3.8 3.6 
 
  
Mean 
(SD) 
 5.8 (0.6) 7.4 (0.5) 11.1 (2.2) -1.7 (0.6) -1.9 (0.6) -7.8 4.6 4.3 
Range 4.9 to 
6.6 
6.8 to 8.3 6.6 to 
13.8 
-2.5 to  
-0.6 
-2.7 to  
-0.8 
-10.0 to  
-2.5 
3.4 to 5.5 3.0 to 6.3 
 
* eTIPS, electronic Targeted Intervention for Psoriasis 
† BIW, twice weekly 
†† QW, once weekly 
 
